Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Repros gets partial reprieve on Proellex hold

This article was originally published in Scrip

Executive Summary

The US FDA reclassified the clinical hold on Repros Therapeutics' studies for its orally selective progesterone antagonist Proellex from a full hold to partial status to permit the firm to conduct a Phase II study to test lower doses of the medicine in patients with endometriosis, a condition which affects about 5 million women of reproductive age in the US and Canada and is characterized by severe pelvic abdominal pain, which generally peaks during menses.



Related Companies